Structured Abstract
Objective
Aortic stiffness is an important predictor of future morbidity and mortality. Diabetes is associated with increased aortic stiffness, but the importance of non-diabetic glucometabolic status for accelerated aortic stiffening is unclear. We tested the hypothesis that adverse glucometabolic status is associated with accelerated aortic stiffening in non-diabetic individuals, independently of known risk factors for arterial stiffening.
Research Design and Methods
Glucometabolic status and other cardiovascular risk factors were assessed at baseline in 2008/09, and carotid femoral pulse wave velocity (cfPWV) at baseline and follow-up in 2012/13, in 4386 non-diabetic participants of the Whitehall II Study.
Results
The mean age of the cohort at cfPWV baseline was 60 years, and 74% were male. cfPWV increased from (mean±SE) 8.30±0.03 to 8.98±0.04 m/s over 4 years of follow-up. At baseline, cfPWV was associated with fasting and 2-hour postload glucose, HbA1c, and HOMA-insulin resistance (HOMA-IR). HbA1c and HOMA-IR were associated with progression of cfPWV after adjusting for physiological confounders and cardiovascular risk factors. A 1SD higher HbA1c and HOMA-IR were associated with greater increases in cfPWV (0.11m/s per 5 years, 95%CI 0.04, 0.18, P=0.003 and 0.09m/s per 5 years, 0.01, 0.17, P=0.03, respectively). Additional adjustment for BMI weakened the association with HOMA-IR but not with HbA1c.
Conclusions
HbA1c is independently associated with accelerated progression of aortic stiffness in non-diabetic individuals. These findings suggest that long-term glucometabolic status, even in non-diabetic individuals, could be an important target for preventative strategies against vascular ageing.